{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:40:28Z","timestamp":1788932428451,"version":"build-2803163510"},"reference-count":372,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Compounds known to be successful in the treatment of alcohol use disorder include the aversive agent, Disulfiram, the glutamatergic NMDA receptor antagonist, Acamprosate, and the opioid receptor antagonists, Naltrexone and Nalmefene. Although all four are effective in maintaining abstinence or reduction of alcohol consumption, only a small percentage of patients receive pharmacological treatment. In addition, many other medications have been investigated for their therapeutic potential in the treatment of alcohol use disorder. In this review we summarize and compare Baclofen, Gabapentin, Topiramate, Ondansetron, Varenicline, Aripiprazole, Quetiapine, Clozapine, Antidepressants, Lithium, Neuropeptide Y, Neuropeptide S, Corticotropin-releasing factor antagonists, Oxytocin, PF-05190457, Memantine, Ifenprodil, Samidorphan, Ondelopran, ABT-436, SSR149415, Mifepristone, Ibudilast, Citicoline, Rimonabant, Surinabant, AM4113 and Gamma-hydroxybutyrate While some have shown promising results in the treatment of alcohol use disorder, others have disappointed and should be excluded from further investigation. Here we discuss the most promising results and highlight medications that deserve further preclinical or clinical study. Effective, patient-tailored treatment will require greater understanding provided by many more preclinical and clinical studies.<\/jats:p>","DOI":"10.3389\/fphar.2022.927703","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:54:24Z","timestamp":1664790864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review"],"prefix":"10.3389","volume":"13","author":[{"given":"Pascal Valentin","family":"Fischler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Soyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Mutschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/14656566.2019.1617273","article-title":"An evaluation of sodium oxybate as a treatment option for narcolepsy","volume":"20","author":"Abad","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1530-0277.2000.tb04555.x","article-title":"Ability of baclofen in reducing alcohol craving and intake: II\u2014preliminary clinical evidence","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.alcohol.2009.09.031","article-title":"Role of the GABAB receptor system in alcoholism and stress: Focus on clinical studies and treatment perspectives","volume":"43","author":"Addolorato","year":"2009","journal-title":"Alcohol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: Secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2174\/138161210791516440","article-title":"Safety and efficacy of baclofen in the treatment of alcohol-dependent patients","volume":"16","author":"Addolorato","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD008581","DOI":"10.1002\/14651858.CD008581.pub2","article-title":"Antidepressants for the treatment of people with co-occurring depression and alcohol dependence","volume":"4","author":"Agabio","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"19r02465","DOI":"10.4088\/PCC.19r02465","article-title":"Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: A meta-analytic review","volume":"21","author":"Ahmed","year":"2019","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1530-0277.2001.tb02289.x","article-title":"Combining ondansetron and naltrexone treats biological alcoholics: Corroboration of self-reported drinking by serum carbohydrate deficient transferrin, A biomarker","volume":"25","author":"Ait-Daoud","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s002130000607","article-title":"Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: Preliminary clinical evidence","volume":"154","author":"Ait-Daoud","year":"","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B12","first-page":"213","article-title":"Treating smoking dependence in depressed alcoholics","volume":"29","author":"Ait-Daoud","year":"","journal-title":"Alcohol Res. Health."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.addbeh.2005.12.029","article-title":"An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants","volume":"31","author":"Ait-Daoud","year":"","journal-title":"Addict. Behav."},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/dar.12306","article-title":"Creating a new problem: The use of baclofen in the management of alcohol use disorder","volume":"35","author":"Akosile","year":"2016","journal-title":"Drug Alcohol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/adb.12177","article-title":"Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats","volume":"20","author":"Alaux-Cantin","year":"2015","journal-title":"Addict. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.alcohol.2021.08.002","article-title":"Onset of alcohol use disorder among alcohol initiates by race\/ethnicity","volume":"97","author":"Alcover","year":"2021","journal-title":"Alcohol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1345\/aph.1L578","article-title":"Topiramate in combat-related posttraumatic stress disorder","volume":"43","author":"Alderman","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bcp.2018.09.008","article-title":"PPAR\u03b1\/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models","volume":"157","author":"Alen","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1530-0277.2010.01412.x","article-title":"High-dose baclofen for suppression of alcohol dependence","volume":"35","author":"Ameisen","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures","volume":"94","author":"Angehagen","year":"2005","journal-title":"J. Neurochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":"A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence","volume":"28","author":"Anton","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: A randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/acer.13417","article-title":"Aripiprazole suppression of drinking in a clinical laboratory paradigm: Influence of impulsivity and self-control","volume":"41","author":"Anton","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/hep.31583","article-title":"Reducing the global burden of alcohol-associated liver disease: A blueprint for action","volume":"73","author":"Asrani","year":"2021","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"104385","DOI":"10.1016\/j.psyneuen.2019.104385","article-title":"Oxytocin modulates alcohol-cue induced functional connectivity in the nucleus accumbens of social drinkers","volume":"109","author":"Bach","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugalcdep.2017.08.003","article-title":"Glial and neuroinflammatory targets for treating substance use disorders","volume":"180","author":"Bachtell","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"B29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.10.040","article-title":"Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling","volume":"131","author":"Balla","year":"2018","journal-title":"Neuropharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-21737-2_6","article-title":"Endocannabinoid system and alcohol abuse disorders","volume":"1162","author":"Basavarajappa","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/alcalc\/agh111","article-title":"Role of the endocannabinoid system in the development of tolerance to alcohol","volume":"40","author":"Basavarajappa","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1111\/acer.12496","article-title":"Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: A randomized controlled pilot trial","volume":"38","author":"Batki","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuropharm.2017.02.004","article-title":"Rat animal models for screening medications to treat alcohol use disorders","volume":"122","author":"Bell","year":"2017","journal-title":"Neuropharmacology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/adb.12106","article-title":"Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence","volume":"20","author":"Bell","year":"2015","journal-title":"Addict. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"134408","DOI":"10.1016\/j.neulet.2019.134408","article-title":"URB597 ameliorates the deleterious effects induced by binge alcohol consumption in adolescent rats","volume":"711","author":"Bellozi","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15r01821","article-title":"Gabapentin therapy in psychiatric disorders: A systematic review","volume":"17","author":"Berlin","year":"2015","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00213-003-1617-5","article-title":"Acute effects of memantine in combination with alcohol in moderate drinkers","volume":"172","author":"Bisaga","year":"2004","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/bcpt.12779","article-title":"Baclofen and alcohol-dependent patients: A real risk of severe self-poisoning","volume":"121","author":"Boels","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-2007-979203","article-title":"Treatment of alcohol withdrawal syndrome with gabapentin","volume":"32","author":"Bonnet","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0014-2999(95)00556-0","article-title":"Neuropeptide Y is a vasoconstrictor and adrenergic modulator in the hamster microcirculation by acting on neuropeptide Y1 and Y2 receptors","volume":"294","author":"Boric","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coph.2005.10.002","article-title":"GABAB receptor: A site of therapeutic benefit","volume":"6","author":"Bowery","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes. Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/02791072.2014.921746","article-title":"Gamma-hydroxybutyrate (GHB): A scoping review of pharmacology, toxicology, motives for use, and user groups","volume":"46","author":"Brennan","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/acer.12445","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence","volume":"38","author":"Brown","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jad.2012.05.006","article-title":"A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence","volume":"143","author":"Brown","year":"2012","journal-title":"J. Affect. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4088\/jcp.v69n0502","article-title":"A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders","volume":"69","author":"Brown","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/JCP.0b013e31814db4c4","article-title":"A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence","volume":"27","author":"Brown","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1176\/appi.ajp.2015.14070857","article-title":"A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder","volume":"172","author":"Brown","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/acer.13928","article-title":"A randomized, double-blind, placebo-controlled trial of citicoline in patients with alcohol use disorder","volume":"43","author":"Brown","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.alcohol.2016.02.006","article-title":"An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder","volume":"53","author":"Brunette","year":"2016","journal-title":"Alcohol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/schbul\/sbl003","article-title":"Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders","volume":"32","author":"Brunette","year":"2006","journal-title":"Schizophr. Bull."},{"key":"B54","first-page":"1346","article-title":"Aripiprazole, alcohol and substance abuse: A review","volume":"16","author":"Brunetti","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s00213-016-4333-7","article-title":"Neuropeptide S differently modulates alcohol-related behaviors in alcohol-preferring and non-preferring rats","volume":"233","author":"Cannella","year":"2016","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/0269881116629126","article-title":"Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series","volume":"30","author":"Caputo","year":"2016","journal-title":"J. Psychopharmacol. Oxf."},{"key":"B58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40263-014-0183-1","article-title":"Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. The GATE 1 trial","volume":"28","author":"Caputo","year":"2014","journal-title":"CNS Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/187152706776359592","article-title":"Neuropeptide y: Role in emotion and alcohol dependence","volume":"5","author":"Carvajal","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/JCP.0000000000000130","article-title":"The effects of quetiapine on sleep in recovering alcohol-dependent subjects: A pilot study","volume":"34","author":"Chakravorty","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e5139","DOI":"10.7759\/cureus.5139","article-title":"A review of samidorphan: A novel opioid antagonist","volume":"11","author":"Chaudhary","year":"2019","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"108495","DOI":"10.1016\/j.drugalcdep.2020.108495","article-title":"Selective serotonin reuptake inhibitors use and hepatocellular carcinoma in patients with alcohol use disorder","volume":"219","author":"Chen","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/fcp.12330","article-title":"Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients","volume":"32","author":"Chevillard","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1530-0277.2011.01675.x","article-title":"Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements","volume":"36","author":"Childs","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1517\/17425255.2014.882317","article-title":"Ondansetron: A review of pharmacokinetics and clinical experience in postoperative nausea and vomiting","volume":"10","author":"Christofaki","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1369-1600.2012.00451.x","article-title":"Binge-like ethanol consumption increases corticosterone levels and neurodegneration whereas occupancy of type II glucocorticoid receptors with mifepristone is neuroprotective","volume":"19","author":"Cippitelli","year":"2014","journal-title":"Addict. Biol."},{"key":"B67","first-page":"15","article-title":"Olanzapine plus samidorphan in subjects with schizophrenia and comorbid alcohol use disorder: Rationale and design for a phase II, double-blind, randomized study","volume":"16","author":"Citrome","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1471-4159.2006.04304.x","article-title":"A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain","volume":"100","author":"Coderre","year":"2007","journal-title":"J. Neurochem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mcna.2021.08.003","article-title":"The spectrum of alcohol use: Epidemiology, diagnosis, and treatment","volume":"106","author":"Cohen","year":"2022","journal-title":"Med. Clin. North Am."},{"key":"B70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1530-0277.2000.tb04554.x","article-title":"Ability of baclofen in reducing alcohol intake and withdrawal severity: I\u2014preclinical evidence","volume":"24","author":"Colombo","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12035-007-0017-y","article-title":"The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: Preclinical evidence","volume":"36","author":"Colombo","year":"2007","journal-title":"Mol. Neurobiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.addbeh.2012.12.018","article-title":"A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil","volume":"38","author":"Corr\u00eaa Filho","year":"2013","journal-title":"Addict. Behav."},{"key":"B73","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuropharm.2017.01.031","article-title":"The role of neuroimmune signaling in alcoholism","volume":"122","author":"Crews","year":"2017","journal-title":"Neuropharmacology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euroneuro.2009.11.001","article-title":"The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review","volume":"20","author":"Crunelle","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.euroneuro.2010.11.001","article-title":"Dose-dependent and sustained effects of varenicline on dopamine D2\/3 receptor availability in rats","volume":"21","author":"Crunelle","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/j.1460-9568.2004.03625.x","article-title":"Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro","volume":"20","author":"Cunningham","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"CD006162","DOI":"10.1002\/14651858.CD006162.pub2","article-title":"Rimonabant for overweight or obesity","volume":"2010","author":"Curioni","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/acer.13562","article-title":"The effects of long-term varenicline administration on ethanol and sucrose seeking and self-administration in male P rats","volume":"42","author":"Czachowski","year":"2018","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40261-017-0616-y","article-title":"Intentional drug overdose involving pregabalin and gabapentin: Findings from the national self-harm registry Ireland, 2007\u20132015","volume":"38","author":"Daly","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B80","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00002018-200427110-00004","article-title":"A benefit-risk assessment of baclofen in severe spinal spasticity","volume":"27","author":"Dario","year":"2004","journal-title":"Drug Saf."},{"key":"B81","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fpsyt.2018.00708","article-title":"The use of baclofen as a treatment for alcohol use disorder: A clinical practice perspective","volume":"9","author":"de Beaurepaire","year":"2018","journal-title":"Front. Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1111\/acer.12854","article-title":"Varenicline for treatment of alcohol dependence: A randomized, placebo-controlled trial","volume":"39","author":"de Bejczy","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/bcp.13127","article-title":"Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects","volume":"83","author":"Denney","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-3-540-33823-9_6","article-title":"Anti-convulsants and anti-depressants","author":"Dickenson","year":"2007","journal-title":"Analg. Elmsford. N. Y)."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/jps.23629","article-title":"Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling","volume":"102","author":"Ding","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/acer.14674","article-title":"Alcohol use disorder severity moderates clinical response to varenicline","volume":"45","author":"Donato","year":"2021","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12888-016-0757-1","article-title":"Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: The MIFCOG trial protocol","volume":"16","author":"Donoghue","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3940(00)00769-2","article-title":"Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin","volume":"280","author":"Dooley","year":"2000","journal-title":"Neurosci. Lett."},{"key":"B89","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","article-title":"The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophr. Bull."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/01.alc.0000130974.50563.04","article-title":"Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy","volume":"28","author":"Dundon","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000333247","article-title":"Baclofen toxicity in patients with advanced nephropathy: Proposal for new labeling","volume":"34","author":"El-Husseini","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1530-0277.2007.00360.x","article-title":"A pilot double-blind treatment trial of memantine for alcohol dependence","volume":"31","author":"Evans","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40211-017-0229-y","article-title":"Oxytocin and the mechanisms of alcohol dependence","volume":"32","author":"Faehrmann","year":"2018","journal-title":"Neuropsychiatr."},{"key":"B96","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: A secondary analysis of 3 randomized clinical trials","volume":"76","author":"Falk","year":"","journal-title":"JAMA Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin Enacarbil extended-release for alcohol use disorder: A randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.physbeh.2019.02.008","article-title":"Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder","volume":"204","author":"Farokhnia","year":"2019","journal-title":"Physiol. Behav."},{"key":"B99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbb.2018.07.004","article-title":"Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?","volume":"172","author":"Farokhnia","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/7854_2020_171","article-title":"GABAB receptors: Anxiety and mood disorders","volume":"52","author":"Felice","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1037\/pha0000232","article-title":"Effects of oxytocin on stress reactivity and craving in veterans with co-occurring PTSD and alcohol use disorder","volume":"27","author":"Flanagan","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"04","DOI":"10.35946\/arcr.v40.2.04","article-title":"Sex differences in the neurobiology of alcohol use disorder","volume":"40","author":"Flores-Bonilla","year":"2020","journal-title":"Alcohol Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-022-03303-4","article-title":"Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: A bayesian meta-analysis","volume":"78","author":"Fluyau","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/09595230500459529","article-title":"Developments in pharmacotherapy for tobacco dependence: Past, present and future","volume":"25","author":"Foulds","year":"2006","journal-title":"Drug Alcohol Rev."},{"key":"B105","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/alcalc\/agt169","article-title":"Self-intoxication with baclofen in alcohol-dependent patients with Co-existing psychiatric illness: An emergency department case series","volume":"49","author":"Franchitto","year":"2014","journal-title":"Alcohol Alcohol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.wnl.0000123695.22623.32","article-title":"Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acer.13326","article-title":"A combination of naltrexone + varenicline retards the expression of a genetic predisposition toward high alcohol drinking","volume":"41","author":"Froehlich","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/acer.13432","article-title":"Varenicline reduces alcohol intake during repeated cycles of alcohol reaccess following deprivation in alcohol-preferring (P) rats","volume":"41","author":"Froehlich","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-neuro-102320-102847","article-title":"Oxytocin, neural plasticity, and social behavior","volume":"44","author":"Froemke","year":"2021","journal-title":"Annu. Rev. Neurosci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","article-title":"A preliminary investigation of varenicline for heavy drinking smokers","volume":"215","author":"Fucito","year":"2011","journal-title":"Psychopharmacology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0074-7742(09)85005-8","article-title":"The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs","volume":"85","author":"Gaetani","year":"2009","journal-title":"Int. Rev. Neurobiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.toxlet.2019.07.001","article-title":"Clinical relevance of ethanol coingestion in patients with GHB\/GBL intoxication","volume":"314","author":"Galicia","year":"2019","journal-title":"Toxicol. Lett."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. Community population with alcohol use disorder: A dose-response, randomized, controlled trial","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence: A review of the evidence","volume":"281","author":"Garbutt","year":"1999","journal-title":"JAMA"},{"key":"B116","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","article-title":"Clinical pharmacology of topiramate: A review","volume":"41","author":"Garnett","year":"2000","journal-title":"Epilepsia"},{"key":"B117","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016","volume":"5","year":"2018","journal-title":"Lancet. Psychiatry"},{"key":"B118","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/13543784.15.3.307","article-title":"Rimonabant: A selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors","volume":"15","author":"Gelfand","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B119","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-009-1704-3","article-title":"Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers","volume":"208","author":"George","year":"2010","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B120","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/alcalc\/agh114","article-title":"Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats","volume":"40","author":"Gessa","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e12768","DOI":"10.1111\/adb.12768","article-title":"Endocannabinoid contributions to alcohol habits and motivation: Relevance to treatment","volume":"25","author":"Gianessi","year":"2019","journal-title":"Addict. Biol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.biopsych.2011.02.004","article-title":"Neuropeptide Y opposes alcohol effects on gamma-aminobutyric acid release in amygdala and blocks the transition to alcohol dependence","volume":"69","author":"Gilpin","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"B123","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.npep.2012.08.001","article-title":"Neuropeptide Y (NPY) in the extended amygdala is recruited during the transition to alcohol dependence","volume":"46","author":"Gilpin","year":"2012","journal-title":"Neuropeptides"},{"key":"B124","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone","volume":"60","author":"Green","year":"2003","journal-title":"Schizophr. Res."},{"key":"B125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.0906e08","article-title":"Treatment of schizophrenia and comorbid substance abuse: Pharmacologic approaches","volume":"67","author":"Green","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"B126","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.forsciint.2018.08.034","article-title":"A multifactorial critical appraisal of substances found in drug facilitated sexual assault cases","volume":"292","author":"Grela","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"B127","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B128","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0165-6147(94)90076-0","article-title":"Neuropeptide Y effector systems: Perspectives for drug development","volume":"15","author":"Grundemar","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"660432","DOI":"10.3389\/fpsyt.2021.660432","article-title":"Comorbid bipolar and alcohol use disorder-A therapeutic challenge","volume":"12","author":"Grunze","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B130","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.addbeh.2010.11.006","article-title":"A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients","volume":"36","author":"Guardia","year":"2011","journal-title":"Addict. Behav."},{"key":"B131","doi-asserted-by":"publisher","first-page":"pyw068","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0043-118955","article-title":"Health care organization - the new German S3-guideline on alcohol-related disorders and its relevance for health care","volume":"57","author":"G\u00fcnthner","year":"2018","journal-title":"Rehabil. (Stuttg)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/npp.2017.257","article-title":"Oxytocin reduces alcohol cue-reactivity in alcohol-dependent rats and humans","volume":"43","author":"Hansson","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B134","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1080\/08897077.2021.2010261","article-title":"Rates of discontinuation and non-publication of trials for the pharmacologic treatment of alcohol use disorder","volume":"43","author":"Hartwell","year":"2022","journal-title":"Subst. Abus."},{"key":"B135","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Hasin","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"B136","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/add.14014","article-title":"Non-medical use of psychoactive prescription drugs is associated with fatal poisoning","volume":"113","author":"Haukka","year":"2018","journal-title":"Addiction"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: A randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"B138","doi-asserted-by":"publisher","first-page":"170403","DOI":"10.1016\/j.peptides.2020.170403","article-title":"Atrial natriuretic peptide (ANP): A novel mechanism for reducing ethanol consumption and seeking behaviors in female alcohol preferring (P) rats","volume":"134","author":"Hauser","year":"2020","journal-title":"Peptides"},{"key":"B139","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jsat.2010.08.009","article-title":"Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: An open-label pilot study","volume":"40","author":"Hays","year":"2011","journal-title":"J. Subst. Abuse Treat."},{"key":"B140","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/alcalc\/agz029","article-title":"The relationship between alcohol craving and insomnia symptoms in alcohol-dependent individuals","volume":"54","author":"He","year":"2019","journal-title":"Alcohol Alcohol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tins.2007.06.006","article-title":"A key role for corticotropin-releasing factor in alcohol dependence","volume":"30","author":"Heilig","year":"2007","journal-title":"Trends Neurosci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/revneuro.2002.13.1.85","article-title":"Brain neuropeptide Y (NPY) in stress and alcohol dependence","volume":"13","author":"Heilig","year":"2002","journal-title":"Rev. Neurosci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1111\/add.15329","article-title":"Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: A systematic review, meta-analysis and meta-regression","volume":"116","author":"Henssler","year":"2021","journal-title":"Addiction"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1517\/13543784.2011.592139","article-title":"Opioid modulators for alcohol dependence","volume":"20","author":"Hillemacher","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B145","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.yhbeh.2018.08.004","article-title":"Prenatal alcohol exposure disrupts male adolescent social behavior and oxytocin receptor binding in rodents","volume":"105","author":"Holman","year":"2018","journal-title":"Horm. Behav."},{"key":"B146","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1037\/pha0000246","article-title":"Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons","volume":"27","author":"Holtyn","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/7854_2020_178","article-title":"GABAB receptors and alcohol use disorders: Preclinical studies","volume":"52","author":"Holtyn","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/acer.12759","article-title":"Subgroup identification in personalized treatment of alcohol dependence","volume":"39","author":"Hou","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3928\/02793695-20131217-01","article-title":"Gabapentin for substance use disorders: Is it safe and appropriate?","volume":"52","author":"Howland","year":"2014","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"B150","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3928\/02793695-20130513-01","article-title":"Mifepristone as a therapeutic agent in psychiatry","volume":"51","author":"Howland","year":"2013","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"B151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2017.11.017","article-title":"Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial","volume":"184","author":"Hurt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/acer.12823","article-title":"Anticraving effect of baclofen in alcohol-dependent patients","volume":"39","author":"Imbert","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/alcalc\/agl037","article-title":"Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking","volume":"41","author":"Ingman","year":"2006","journal-title":"Alcohol Alcohol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1111\/j.1530-0277.2008.00799.x","article-title":"Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption","volume":"32","author":"Jacquot","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: A randomised controlled trial","volume":"361","author":"Johnson","year":"","journal-title":"Lancet"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1097\/01.ALC.0000095635.46911.5D","article-title":"Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals","volume":"27","author":"Johnson","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","article-title":"Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: From hypotheses to preliminary clinical evidence","volume":"24","author":"Johnson","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"B161","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2174\/138161210791516404","article-title":"Topiramate in the new generation of drugs: Efficacy in the treatment of alcoholic patients","volume":"16","author":"Johnson","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"B162","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/BF02247375","article-title":"Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: A preliminary study in healthy male volunteers","volume":"112","author":"Johnson","year":"1993","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B163","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2165\/00023210-200519100-00005","article-title":"Recent advances in the development of treatments for alcohol and cocaine dependence: Focus on topiramate and other modulators of GABA or glutamate function","volume":"19","author":"Johnson","year":"2005","journal-title":"CNS Drugs"},{"key":"B164","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00213-002-1002-9","article-title":"Ondansetron reduces the craving of biologically predisposed alcoholics","volume":"160","author":"Johnson","year":"2002","journal-title":"Psychopharmacology"},{"key":"B165","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial","volume":"284","author":"Johnson","year":"","journal-title":"JAMA"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: A randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"B168","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","article-title":"Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings","volume":"75","author":"Johnson","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"B170","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: A systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front. Psychiatry"},{"key":"B171","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/JCP.0b013e3180ca86e5","article-title":"A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism","volume":"27","author":"Kampman","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"Kapil","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00213-015-4089-5","article-title":"Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436","volume":"233","author":"Katz","year":"","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e00628","DOI":"10.1002\/brb3.628","article-title":"Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial","volume":"7","author":"Katz","year":"2017","journal-title":"Brain Behav."},{"key":"B175","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/acer.12996","article-title":"Single-dose interaction study of the arginine vasopressin type 1B receptor antagonist ABT-436 and alcohol in moderate alcohol drinkers","volume":"40","author":"Katz","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: A review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/ajhp\/61.21.2272","article-title":"Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1","volume":"61","author":"Kenna","year":"","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/ajhp\/61.22.2380","article-title":"Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2","volume":"61","author":"Kenna","year":"","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"B179","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.alcohol.2014.04.005","article-title":"Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol dependent women: Exploratory findings","volume":"48","author":"Kenna","year":"","journal-title":"Alcohol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/acer.12410","article-title":"Ondansetron reduces naturalistic drinking in non-treatment seeking alcohol dependent individuals with the LL 5\u2032-HTTLPR genotype: A laboratory study","volume":"38","author":"Kenna","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B181","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.2174\/138161210791516341","article-title":"Acamprosate: How, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy","volume":"16","author":"Kiefer","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"B182","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.pnpbp.2008.01.009","article-title":"Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia","volume":"32","author":"Kim","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B183","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/2279-042X.200987","article-title":"Quetiapine misuse and abuse: Is it an atypical paradigm of drug seeking behavior?","volume":"6","author":"Kim","year":"2017","journal-title":"J. Res. Pharm. Pract."},{"key":"B184","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00213-019-05233-z","article-title":"Oxytocin attenuates stress-induced reinstatement of alcohol seeking behavior in male and female mice","volume":"236","author":"King","year":"2019","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B185","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/acer.13359","article-title":"Oxytocin reduces ethanol self-administration in mice","volume":"41","author":"King","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B186","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mayocpiqo.2021.01.013","article-title":"Naltrexone initiation in the inpatient setting for alcohol use disorder: A systematic review of clinical outcomes","volume":"5","author":"Kirchoff","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"B187","doi-asserted-by":"publisher","first-page":"e642","DOI":"10.4088\/JCP.12r08178","article-title":"Antipsychotics for primary alcohol dependence: A systematic review and meta-analysis of placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"B188","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/sj.npp.1300844","article-title":"Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil","volume":"31","author":"Kobayashi","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B189","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.psyneuen.2003.09.004","article-title":"The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions","volume":"29","author":"Koenig","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"B190","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pbb.2019.01.007","article-title":"Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies","volume":"179","author":"Kohno","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B191","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10517-017-3946-0","article-title":"Non-competitive NMDA receptor antagonist hemantane reduces ethanol consumption in long-term alcohol experienced rats","volume":"164","author":"Kolik","year":"2017","journal-title":"Bull. Exp. Biol. Med."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1017\/S1461145714000510","article-title":"GRIK1 genotype moderates topiramate\u2019s effects on daily drinking level, expectations of alcohol\u2019s positive effects and desire to drink","volume":"17","author":"Kranzler","year":"","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1530-0277.2011.01659.x","article-title":"Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence","volume":"36","author":"Kranzler","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/adb.12207","article-title":"Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking","volume":"21","author":"Kranzler","year":"2016","journal-title":"Addict. Biol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: Moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"","journal-title":"Am. J. Psychiatry"},{"key":"B196","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1530-0277.2011.01609.x","article-title":"Comparison of alcoholism subtypes as moderators of the response to sertraline treatment","volume":"36","author":"Kranzler","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"key":"B198","doi-asserted-by":"publisher","first-page":"e13130","DOI":"10.1111\/adb.13130","article-title":"Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials","volume":"27","author":"Kranzler","year":"2022","journal-title":"Addict. Biol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41386-020-00945-9","article-title":"Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder","volume":"46","author":"Kranzler","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B200","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early- versus late-onset alcoholics: A prospective, open-label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B201","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/acer.12619","article-title":"N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers","volume":"39","author":"Krishnan-Sarin","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1176\/ajp.2007.164.3.519","article-title":"Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients","volume":"164","author":"Krupitsky","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"B203","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17116\/jnevro20151156153-62","article-title":"Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan\u00ae) for alcohol dependence","volume":"115","author":"Krupitsky","year":"2015","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/npp.2014.306","article-title":"The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: A randomized controlled experimental medicine study","volume":"40","author":"Kwako","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B205","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/adb.12149","article-title":"Neuropeptide S receptor gene variant and environment: Contribution to alcohol use disorders and alcohol consumption","volume":"20","author":"Laas","year":"2015","journal-title":"Addict. Biol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.alcohol.2006.08.001","article-title":"SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats","volume":"39","author":"Lallemand","year":"2006","journal-title":"Alcohol"},{"key":"B207","first-page":"RA1","article-title":"Targets for antiepileptic drugs in the synapse","volume":"13","author":"Landmark","year":"2007","journal-title":"Med. Sci. Monit."},{"key":"B208","first-page":"708\u2013711","article-title":"Trends in alcohol use disorder treatment utilization and setting from 2008 to 2017","volume-title":"Psychiatr. Serv.","author":"Larsen","year":"2022"},{"key":"B209","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.alc.0000113413.37910.d7","article-title":"Pharmacological treatment of alcohol abuse\/dependence with psychiatric comorbidity","volume":"28","author":"Le Fauve","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B210","doi-asserted-by":"publisher","first-page":"107788","DOI":"10.1016\/j.neuropharm.2019.107788","article-title":"Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers","volume":"170","author":"Lee","year":"","journal-title":"Neuropharmacology"},{"key":"B211","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psyneuen.2017.07.481","article-title":"Effect of alcohol use disorder on oxytocin peptide and receptor mRNA expression in human brain: A post-mortem case-control study","volume":"85","author":"Lee","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"B212","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41380-018-0064-y","article-title":"The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: Preclinical safety experiments and a phase 1b human laboratory study","volume":"25","author":"Lee","year":"","journal-title":"Mol. Psychiatry"},{"key":"B213","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/FBP.0000000000000258","article-title":"Oxytocin for the treatment of drug and alcohol use disorders","volume":"27","author":"Lee","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/acer.13640","article-title":"Add-on memantine treatment for bipolar II disorder comorbid with alcohol dependence: A 12-week follow-up study","volume":"42","author":"Lee","year":"2018","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B215","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/alcalc\/agx072","article-title":"Baclofen self-poisoning in the era of changing indication: Multicentric reports to a French poison control centre","volume":"52","author":"L\u00e9ger","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41386-021-01142-y","article-title":"The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: Why these findings matter","volume":"46","author":"Leggio","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"B217","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1358\/dnp.2010.23.3.1429490","article-title":"Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases","volume":"23","author":"Leggio","year":"2010","journal-title":"Drug News Perspect."},{"key":"B218","first-page":"273","article-title":"Evaluation of lithium treatment in alcoholism","volume":"28","author":"Lejoyeux","year":"1993","journal-title":"Alcohol Alcohol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"CD006266","DOI":"10.1002\/14651858.CD006266.pub2","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"B220","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B221","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1742-6723.2006.00805.x","article-title":"Baclofen overdose: Defining the spectrum of toxicity","volume":"18","author":"Leung","year":"2006","journal-title":"Emerg. Med. Australas."},{"key":"B222","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.drugalcdep.2013.06.032","article-title":"Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: A 12-week, randomized, placebo-controlled trial","volume":"133","author":"Likhitsathian","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"B223","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B224","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J. Addict. Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/187152710790966605","article-title":"Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism","volume":"9","author":"Lowery","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B226","doi-asserted-by":"publisher","first-page":"811401","DOI":"10.3389\/fnins.2021.811401","article-title":"Behavioral profiles of adolescent alcohol-preferring\/non-preferring (P\/NP) and high\/low alcohol-drinking (HAD\/LAD) rats are dependent on line but not sex","volume":"15","author":"Lundberg","year":"2021","journal-title":"Front. Neurosci."},{"key":"B227","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-011-2253-0","article-title":"Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse","volume":"217","author":"Lynch","year":"2011","journal-title":"Psychopharmacol. Berl."},{"key":"B228","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/187152710790966623","article-title":"Blockade of the cannabinoid CB1 receptor and alcohol dependence: Preclinical evidence and preliminary clinical data","volume":"9","author":"Maccioni","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.psyneuen.2011.02.015","article-title":"A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research","volume":"36","author":"MacDonald","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"B230","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0014-2999(99)00393-3","article-title":"Ifenprodil influences changes in mouse behaviour related to acute and chronic ethanol administration","volume":"377","author":"Malinowska","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2174\/1389200219666171207122227","article-title":"Sodium oxybate therapy for alcohol withdrawal syndrome and keeping of alcohol abstinence","volume":"19","author":"Mannucci","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"B232","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10550490500419110","article-title":"A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal","volume":"15","author":"Mariani","year":"2006","journal-title":"Am. J. Addict."},{"key":"B233","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/1073858420960111","article-title":"Oxytocin and the neurobiology of prosocial behavior","volume":"27","author":"Marsh","year":"2021","journal-title":"Neuroscientist."},{"key":"B234","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/hup.944","article-title":"Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics","volume":"23","author":"Martinotti","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/0269881108089596","article-title":"Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. naltrexone","volume":"23","author":"Martinotti","year":"2009","journal-title":"J. Psychopharmacol. Oxf."},{"key":"B236","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/13543784.2016.1175431","article-title":"Aripiprazole for relapse prevention and craving in alcohol use disorder: Current evidence and future perspectives","volume":"25","author":"Martinotti","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B237","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.pnpbp.2003.11.020","article-title":"Add-on gabapentin in the treatment of opiate withdrawal","volume":"28","author":"Mart\u0131\u0301nez-Raga","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B238","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: A randomized clinical trial.","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"B239","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder","volume":"27","author":"Mason","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B240","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"B241","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/eat.22114","article-title":"A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder","volume":"46","author":"McElroy","year":"2013","journal-title":"Int. J. Eat. Disord."},{"key":"B242","doi-asserted-by":"publisher","first-page":"arcr.v40.1.01","DOI":"10.35946\/arcr.v40.1.01","article-title":"Alcohol use disorder and depressive disorders","volume":"40","author":"McHugh","year":"2019","journal-title":"Alcohol Res."},{"key":"B243","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"B244","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1060028015620800","article-title":"Gabapentin: Abuse, dependence, and withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B245","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/JCP.0b013e3182870551","article-title":"Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: A randomized, placebo-controlled pilot trial","volume":"33","author":"Meszaros","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1360-0443.2002.00019.x","article-title":"Mesa grande: A methodological analysis of clinical trials of treatments for alcohol use disorders","volume":"97","author":"Miller","year":"2002","journal-title":"Addiction"},{"key":"B247","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/acer.14352","article-title":"Effects of alcohol cue reactivity on subsequent treatment outcomes among treatment-seeking individuals with alcohol use disorder: A multisite randomized, double-blind, placebo-controlled clinical trial of varenicline","volume":"44","author":"Miranda","year":"2020","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B248","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.toxlet.2017.05.030","article-title":"Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse","volume":"277","author":"Mir\u00f3","year":"2017","journal-title":"Toxicol. Lett."},{"key":"B249","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/ADM.0000000000000213","article-title":"Intranasal oxytocin selectively modulates social perception, craving, and approach behavior in subjects with alcohol use disorder","volume":"10","author":"Mitchell","year":"2016","journal-title":"J. Addict. Med."},{"key":"B250","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"key":"B251","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/7854_2015_424","article-title":"Misuse and associated harms of quetiapine and other atypical antipsychotics","volume":"34","author":"Montebello","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B252","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1037\/a0035215","article-title":"Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol\u2019s reinforcing effects in male Alcohol Preferring (P) rats","volume":"22","author":"Moore","year":"2014","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: Multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"B254","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol"},{"key":"B255","first-page":"153","article-title":"Endocannabinoid system: An overview of its potential in current medical practice","volume":"30","author":"Mouslech","year":"2009","journal-title":"Neuro Endocrinol. Lett."},{"key":"B256","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1517\/14656566.2014.876008","article-title":"Current pharmacological treatment approaches for alcohol dependence","volume":"15","author":"M\u00fcller","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","article-title":"High-dose baclofen for the treatment of alcohol dependence (baclad study): A randomized, placebo-controlled trial","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-0042-103592","article-title":"Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence","volume":"49","author":"Mutschler","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"B259","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B260","doi-asserted-by":"publisher","first-page":"768318","DOI":"10.3389\/fpsyt.2021.768318","article-title":"Depression and\/or PTSD comorbidity affects response to antidepressants in those with alcohol use disorder","volume":"12","author":"Na","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B261","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/alcalc\/agz045","article-title":"Effect of selective serotonin reuptake inhibitors on healthcare utilization in patients with post-traumatic stress disorder and alcohol use disorder","volume":"54","author":"Naglich","year":"2019","journal-title":"Alcohol Alcohol"},{"key":"B262","doi-asserted-by":"publisher","first-page":"245","DOI":"10.15288\/jsad.2013.74.245","article-title":"Effects of memantine on event-related potential, oscillations, and complexity in individuals with and without family histories of alcoholism","volume":"74","author":"Narayanan","year":"2013","journal-title":"J. Stud. Alcohol Drugs"},{"key":"B263","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/00952990.2012.730590","article-title":"Aripiprazole in an animal model of chronic alcohol consumption and dopamine D\u2082 receptor occupancy in rats","volume":"39","author":"Nirogi","year":"2013","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B264","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1521-0391.2013.12037.x","article-title":"Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co-occurring alcohol and nicotine addiction?","volume":"22","author":"Nocente","year":"2013","journal-title":"Am. J. Addict."},{"key":"B265","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","article-title":"Clozapine as a model for antipsychotic development","volume":"14","author":"Nucifora","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B266","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis","volume":"291","author":"Nunes","year":"2004","journal-title":"JAMA"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/j.1530-0277.2010.01220.x","article-title":"Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice","volume":"34","author":"Oberlin","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B268","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1111\/acer.13849","article-title":"Effects of the opioid system modulator, samidorphan, on measures of alcohol consumption and patient-reported outcomes in adults with alcohol dependence","volume":"42","author":"O\u2019Malley","year":"2018","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B269","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jamapsychiatry.2017.3544","article-title":"Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: A randomized clinical trial","volume":"75","author":"O\u2019Malley","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B270","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pbb.2005.07.021","article-title":"Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat","volume":"82","author":"Overstreet","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B271","first-page":"CD008544","article-title":"Anticonvulsants for alcohol dependence","volume-title":"Cochrane Database Syst. Rev.","author":"Pani","year":"2014"},{"key":"B272","doi-asserted-by":"publisher","first-page":"102110","DOI":"10.1016\/j.cpr.2021.102110","article-title":"Expanding the continuum of substance use disorder treatment: Nonabstinence approaches","volume":"91","author":"Paquette","year":"2022","journal-title":"Clin. Psychol. Rev."},{"key":"B273","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/jcph.1343","article-title":"Abuse potential of samidorphan: A phase I, oxycodone-pentazocine-naltrexone-and placebo-controlled study","volume":"59","author":"Pathak","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1530-0277.2012.01958.x","article-title":"Intranasal oxytocin blocks alcohol withdrawal in human subjects","volume":"37","author":"Pedersen","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B275","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine","volume":"31","author":"Perucca","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"B276","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1530-0277.2000.tb04648.x","article-title":"Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype","volume":"24","author":"Pettinati","year":"2000","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B277","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/gbb.12189","article-title":"Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation","volume":"14","author":"Phillips","year":"2015","journal-title":"Genes. Brain Behav."},{"key":"B278","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.drugalcdep.2013.06.019","article-title":"Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence","volume":"133","author":"Plebani","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"B280","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drugalcdep.2011.08.025","article-title":"Results of an initial clinical trial of varenicline for the treatment of cocaine dependence","volume":"121","author":"Plebani","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"B281","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1111\/acer.13507","article-title":"The corticotropin releasing factor receptor 1 in alcohol use disorder: Still a valid drug target?","volume":"41","author":"Pomrenze","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B282","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: A randomized, double-blind, placebo-controlled trial with 1Year follow-up","volume":"52","author":"Ponizovsky","year":"2015","journal-title":"J. Subst. Abuse Treat."},{"key":"B283","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1176\/appi.ajp.2021.20121757","article-title":"Effects of gabapentin on dorsal anterior cingulate cortex GABA and glutamate levels and their associations with abstinence in alcohol use disorder: A randomized clinical trial","volume":"178","author":"Prisciandaro","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"B284","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3109\/10826084.2015.1133646","article-title":"Safety of varenicline for smoking cessation in psychiatric and addicts patients","volume":"51","author":"Raich","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"B285","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.pharep.2015.10.010","article-title":"The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol","volume":"68","author":"Ratajczak","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"B286","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/npp.2017.10","article-title":"Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: A randomized, placebo-controlled, human laboratory trial","volume":"42","author":"Ray","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B287","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00213-011-2287-3","article-title":"A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving","volume":"217","author":"Ray","year":"2011","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B288","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00952990.2014.927881","article-title":"Varenicline, naltrexone, and their combination for heavy-drinking smokers: Preliminary neuroimaging findings","volume":"41","author":"Ray","year":"2015","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B289","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1465-3362.2010.00185.x","article-title":"Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature","volume":"29","author":"Ray","year":"2010","journal-title":"Drug Alcohol Rev."},{"key":"B290","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1073858405276405","article-title":"Neuropeptide S and its receptor: A newly deorphanized G protein-coupled receptor system","volume":"11","author":"Reinscheid","year":"2005","journal-title":"Neuroscientist"},{"key":"B291","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13059-015-0593-5","article-title":"Identifying candidate drivers of alcohol dependence-induced excessive drinking by assembly and interrogation of brain-specific regulatory networks","volume":"16","author":"Repunte-Canonigo","year":"2015","journal-title":"Genome Biol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"B293","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/bjp.2008.96","article-title":"Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice","volume":"154","author":"Rizzi","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B294","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00213-017-4667-9","article-title":"Effects of varenicline on alcohol cue reactivity in heavy drinkers","volume":"234","author":"Roberts","year":"2017","journal-title":"Psychopharmacology"},{"key":"B295","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/acer.14771","article-title":"Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder","volume":"46","author":"Robinson","year":"2022","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B296","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/bs.irn.2017.06.005","article-title":"The role of neuropeptide Y (NPY) in alcohol and drug abuse disorders","volume":"136","author":"Robinson","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B297","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: Physiology and pharmacology","volume":"40","author":"Rodr\u00edguez de Fonseca","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"B298","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2174\/0929867324666170316120836","article-title":"Targeting NPY, CRF\/UCNs and NPS neuropeptide systems to treat alcohol use disorder (AUD)","volume":"24","author":"Rodriguez","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"B299","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"B300","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","article-title":"Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation","volume":"25","author":"Rolland","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B301","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/add.14191","article-title":"Baclofen: Its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis","volume":"113","author":"Rose","year":"2018","journal-title":"Addiction"},{"key":"B302","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0924-9338(01)00562-4","article-title":"Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: A case-series","volume":"16","author":"Roy Chengappa","year":"2001","journal-title":"Eur. Psychiatry"},{"key":"B303","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1530-0277.2009.01070.x","article-title":"Neuropeptide S receptor gene expression in alcohol withdrawal and protracted abstinence in postdependent rats","volume":"34","author":"Ruggeri","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B304","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/bs.irn.2017.06.007","article-title":"Contribution of urocortin to the development of excessive drinking","volume":"136","author":"Ryabinin","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B305","doi-asserted-by":"publisher","first-page":"842609","DOI":"10.3389\/fpsyt.2022.842609","article-title":"Barriers and breakthroughs in targeting the oxytocin system to treat alcohol use disorder","volume":"13","author":"Ryabinin","year":"2022","journal-title":"Front. Psychiatry"},{"key":"B306","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/npp.2016.214","article-title":"A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence","volume":"42","author":"Ryan","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B307","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/00952990.2017.1292279","article-title":"Management of comorbid bipolar disorder and substance use disorders","volume":"43","author":"Salloum","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B308","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"key":"B309","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/npp.2017.298","article-title":"Dopaminergic genetic variation influences aripiprazole effects on alcohol self-administration and the neural response to alcohol cues in a randomized trial","volume":"43","author":"Schacht","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B310","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/15563650.2012.702218","article-title":"The clinical toxicology of \u03b3-hydroxybutyrate, \u03b3-butyrolactone and 1, 4-butanediol","volume":"50","author":"Schep","year":"2012","journal-title":"Clin. Toxicol."},{"key":"B311","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/npp.2016.27","article-title":"Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys","volume":"41","author":"Schindler","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B312","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/164_2017_86","article-title":"Corticotropin-releasing factor (CRF) neurocircuitry and Neuropharmacology in alcohol drinking","volume":"248","author":"Schreiber","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"B313","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/npp.2016.61","article-title":"The CRF1 antagonist verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, but not of anti-craving effects","volume":"41","author":"Schwandt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B314","doi-asserted-by":"publisher","first-page":"0","DOI":"10.5604\/01.3001.0010.3798","article-title":"Ibudilast: A non-selective phosphodiesterase inhibitor in brain disorders","volume":"71","author":"Schwenkgrub","year":"2017","journal-title":"Postepy Hig. Med. Dosw."},{"key":"B315","first-page":"1","article-title":"Citicoline: Pharmacological and clinical review, 2006 update","volume":"28","author":"Secades","year":"2006","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"B316","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"B317","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/acer.12093","article-title":"Mifepristone pretreatment reduces ethanol withdrawal severity in vivo","volume":"37","author":"Sharrett-Field","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B318","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/npr2.12028","article-title":"Anticraving therapy for alcohol use disorder: A clinical review","volume":"38","author":"Shen","year":"","journal-title":"Neuropsychopharmacol. Rep."},{"key":"B319","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/npr2.12028","article-title":"Anticraving therapy for alcohol use disorder: A clinical review","volume":"38","author":"Shen","year":"","journal-title":"Neuropsychopharmacol. Rep."},{"key":"B320","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","article-title":"Double-blind randomized clinical trial of prazosin for alcohol use disorder","volume":"175","author":"Simpson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B321","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"B322","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse, and diversion: A systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-28720-6","article-title":"Behavioral neurobiology of alcohol addiction. Preface","volume":"13","author":"Sommer","year":"2013","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B324","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","article-title":"Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial","volume":"28","author":"Soyka","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"B325","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/15622975.2016.1246752","article-title":"Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision","volume":"18","author":"Soyka","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"B326","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-0035-1547237","article-title":"Recent developments in pharmacotherapy of alcoholism","volume":"48","author":"Soyka","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"B327","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism - an update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"B328","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pnpbp.2015.11.003","article-title":"Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine","volume":"70","author":"Soyka","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B329","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1517\/14656566.7.17.2341","article-title":"New pharmacological approaches for the treatment of alcoholism","volume":"7","author":"Soyka","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"B330","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1152\/physrev.00013.2008","article-title":"Alcoholism: A systems approach from molecular physiology to addictive behavior","volume":"89","author":"Spanagel","year":"2009","journal-title":"Physiol. Rev."},{"key":"B331","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/npp.2011.327","article-title":"Central neuropeptide Y modulates binge-like ethanol drinking in C57BL\/6J mice via Y1 and Y2 receptors","volume":"37","author":"Sparrow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B332","doi-asserted-by":"publisher","first-page":"27P-32P","DOI":"10.1016\/j.amjcard.2007.10.011","article-title":"Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: Safety, tolerability, and therapeutic potential","volume":"100","author":"Steinberg","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"B333","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugalcdep.2010.06.022","article-title":"Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies","volume":"114","author":"Steinberg","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"B334","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.physbeh.2017.07.021","article-title":"Oxytocin reduces alcohol consumption in prairie voles","volume":"179","author":"Stevenson","year":"2017","journal-title":"Physiol. Behav."},{"key":"B335","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/npr2.12001","article-title":"A randomized controlled study of the effect of ifenprodil on alcohol use in patients with alcohol dependence","volume":"38","author":"Sugaya","year":"2018","journal-title":"Neuropsychopharmacol. Rep."},{"key":"B336","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/15563650.2011.654209","article-title":"Baclofen overdose mimicking brain death","volume":"50","author":"Sullivan","year":"2012","journal-title":"Clin. Toxicol."},{"key":"B337","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.drugalcdep.2018.08.011","article-title":"Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist\/CB2R agonist aminoalkylindole derivatives in mice","volume":"192","author":"Tai","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B338","doi-asserted-by":"publisher","first-page":"109287","DOI":"10.1016\/j.drugalcdep.2022.109287","article-title":"Alcohol use disorder: An analysis of the evidence underpinning clinical practice guidelines","volume":"232","author":"Tanner","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"B339","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.npep.2015.09.007","article-title":"The role of Neuropeptide Y in fear conditioning and extinction","volume":"55","author":"Tasan","year":"2016","journal-title":"Neuropeptides"},{"key":"B340","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/alcalc\/agv090","article-title":"Variation in the serotonin transporter gene and alcoholism: Risk and response to pharmacotherapy","volume":"51","author":"Thompson","year":"2016","journal-title":"Alcohol Alcohol"},{"key":"B341","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1258\/ebm.2010.009331","article-title":"Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety","volume":"235","author":"Thorsell","year":"2010","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B342","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/0269881111431623","article-title":"Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: A randomized controlled clinical trial","volume":"26","author":"Tonstad","year":"2012","journal-title":"J. Psychopharmacol. Oxf."},{"key":"B343","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.09.004","article-title":"Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis","volume":"78","author":"Torrens","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"B344","doi-asserted-by":"publisher","first-page":"e2006421","DOI":"10.1371\/journal.pbio.2006421","article-title":"Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala","volume":"17","author":"Tunstall","year":"2019","journal-title":"PLoS Biol."},{"key":"B345","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B346","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clinthera.2014.10.001","article-title":"Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers","volume":"37","author":"Turncliff","year":"2015","journal-title":"Clin. Ther."},{"key":"B347","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: A first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B348","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"van den Brink","year":"2018","journal-title":"Addict. Biol."},{"key":"B349","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1021\/jm400268b","article-title":"Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse","volume":"56","author":"Vasiljevik","year":"2013","journal-title":"J. Med. Chem."},{"key":"B350","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1523\/JNEUROSCI.0069-12.2012","article-title":"Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats","volume":"32","author":"Vendruscolo","year":"2012","journal-title":"J. Neurosci."},{"key":"B351","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1172\/JCI79828","article-title":"Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals","volume":"125","author":"Vendruscolo","year":"2015","journal-title":"J. Clin. Investig."},{"key":"B352","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuropharm.2005.01.002","article-title":"The role of the NMDA receptor in alcohol relapse: A pharmacological mapping study using the alcohol deprivation effect","volume":"48","author":"Vengeliene","year":"2005","journal-title":"Neuropharmacology"},{"key":"B353","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/jnc.13350","article-title":"Long-lasting effect of NMDA receptor antagonist memantine on ethanol-cue association and relapse","volume":"135","author":"Vengeliene","year":"2015","journal-title":"J. Neurochem."},{"key":"B354","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/08897070309511541","article-title":"Gabapentin for the treatment of ethanol withdrawal","volume":"24","author":"Voris","year":"2003","journal-title":"Subst. Abus."},{"key":"B355","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/j.1530-0277.2008.00783.x","article-title":"Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control","volume":"32","author":"Voronin","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B356","doi-asserted-by":"publisher","first-page":"108964","DOI":"10.1016\/j.drugalcdep.2021.108964","article-title":"Pharmacotherapy for alcohol use disorders - unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden","volume":"227","author":"Wallhed Finn","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B357","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/S0028-3908(97)00118-4","article-title":"The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome","volume":"36","author":"Watson","year":"1997","journal-title":"Neuropharmacology"},{"key":"B358","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1523\/JNEUROSCI.22-09-03332.2002","article-title":"Behavioral neurobiology of alcohol addiction: Recent advances and challenges","volume":"22","author":"Weiss","year":"","journal-title":"J. Neurosci."},{"key":"B359","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1592\/phco.26.3.375","article-title":"Topiramate for migraine prevention","volume":"26","author":"Wenzel","year":"2006","journal-title":"Pharmacotherapy"},{"key":"B360","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"B361","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3109\/00952990.2014.925467","article-title":"Citicoline in addictive disorders: A review of the literature","volume":"40","author":"Wignall","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"B362","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/ADM.0000000000000760","article-title":"Can individuals with alcohol use disorder sustain non-abstinent recovery? Non-abstinent outcomes 10 Years after alcohol use disorder treatment","volume":"15","author":"Witkiewitz","year":"2021","journal-title":"J. Addict. Med."},{"key":"B363","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/acer.12257","article-title":"A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence","volume":"38","author":"Wong","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B364","article-title":"Gamma-hydroxybutyric acid (GHB). Critical review report.","volume-title":"Expert committee on drug dependence 35th meeting, hammamet, tunesia. 4 - 8 june 2012","author":"World Health Organization","year":""},{"key":"B365","first-page":"1","article-title":"WHO expert committee on drug dependence","author":"World Health Organization","year":"","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"B366","doi-asserted-by":"publisher","first-page":"108343","DOI":"10.1016\/j.jsat.2021.108343","article-title":"Emergency department presentation of opioid use disorder and alcohol use disorder","volume":"127","author":"Xierali","year":"2021","journal-title":"J. Subst. Abuse Treat."},{"key":"B367","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neulet.2018.09.006","article-title":"Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway","volume":"686","author":"Yuanyuan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B368","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.irn.2017.08.002","article-title":"The role of the ghrelin system in drug addiction","volume":"136","author":"Zallar","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"B369","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/j.1530-0277.2011.01532.x","article-title":"Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats","volume":"35","author":"Zhou","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B370","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/acer.13544","article-title":"V1b receptor antagonist SSR149415 and naltrexone synergistically decrease excessive alcohol drinking in male and female mice","volume":"42","author":"Zhou","year":"2018","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B371","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.drugalcdep.2012.12.017","article-title":"Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism","volume":"128","author":"Zorrilla","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"B372","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.yfrne.2014.01.001","article-title":"Corticotropin releasing factor: A key role in the neurobiology of addiction","volume":"35","author":"Zorrilla","year":"2014","journal-title":"Front. Neuroendocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.927703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:54:47Z","timestamp":1664790887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.927703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":372,"alternative-id":["10.3389\/fphar.2022.927703"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.927703","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"article-number":"927703"}}